Medical treatment of early stage and rare histological variants of epithelial ovarian cancer

Nicoletta Tomasi Cont, Annamaria Ferrero, Fedro Alessandro Peccatori, Marta D'Alonzo, Giovanni Codacci-Pisanelli, Nicoletta Colombo, Nicoletta Biglia

Research output: Contribution to journalArticlepeer-review


Epithelial ovarian cancer is often considered a single pathological entity, but increasing evidence suggests that it is rather a group of different neoplasms, each with unique pathological characteristics, molecular features, and clinical behaviours. This heterogeneity accounts for the different sensitivity to antineoplastic drugs and makes the treatment of ovarian tumours a challenge. For early-stage disease, as well as for heavily pre-treated patients with recurrent ovarian cancer, the benefit of chemotherapy remains uncertain. Clear-cell, mucinous, low-grade serous, and endometrioid carcinomas show different molecular characteristics, which require different therapeutic approaches. In the era of personalised cancer medicine, understanding the pathogenesis and the genetic background of each subtype of epithelial ovarian tumour may lead to a tailored therapy, maximising the benefits of specific treatments and possibly reducing the side effects. Furthermore, personal factors, such as the patient's performance status, should be taken into account in the management of ovarian cancer, with the aim of safeguarding the patients' quality of life.

Original languageEnglish
Article number584
Publication statusPublished - Oct 22 2015


  • Biological markers
  • Ovarian neoplasm
  • Personalised medicine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Medical treatment of early stage and rare histological variants of epithelial ovarian cancer'. Together they form a unique fingerprint.

Cite this